Managing metastatic hormone-sensitive prostate cancer with apalutamide
Part of Cancer, Kidney & urinary clinical trials.
This trial tests a proactive management approach for men with metastatic hormone-sensitive prostate cancer who are starting apalutamide. It aims to see if this model helps improve how well the treatment works and how patients feel.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a man aged 18 or older.
- You have prostate cancer that has spread and still responds to hormone therapy.
- You are about to start or have recently started apalutamide with hormone therapy.
- You are able to take pills by mouth.
- You agree to use condoms during sexual activity and not to donate sperm while on the study and for 3 months after.
- You do not have certain other serious health conditions or prior treatments that would interfere with the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new oral drug, MRT-2359, combined with apalutamide (a standard hormone therapy) in men with a specific type of prostate cancer that has stopped responding to hormone treatment. The goal is to see if the combination can slow or stop the cancer's growth.
This trial tests if adding docetaxel chemotherapy helps men whose PSA hasn't dropped enough after at least 6 months of standard hormone therapy (ADT) plus an ARPI pill (like abiraterone or enzalutamide) for metastatic prostate cancer that still responds to hormones.
This study looks at how well men with prostate cancer that has spread and is still hormone-sensitive stick to taking the drug apalutamide. It aims to understand real-world use and quality of life.
This trial tests whether adding a chemotherapy drug (docetaxel) to your current treatment (apalutamide) can help control prostate cancer that has spread and hasn't responded as well as hoped to apalutamide alone.
This trial studies whether adding apalutamide to standard hormone therapy (ADT) improves outcomes for men with metastatic hormone-sensitive prostate cancer. Some people may also receive local treatments (like surgery or radiotherapy) to control the prostate and nearby areas.
This Phase 2 trial studies whether removing the prostate (cytoreductive radical prostatectomy) and targeting visible metastases with radiation can improve outcomes for men with newly diagnosed metastatic prostate cancer who are already starting apalutamide plus hormone therapy (ADT). It’s meant to see if treating “visible spots” after the initial medication helps the cancer control last longer.
Hear when a new Prostate Cancer (Adenocarcinoma) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.